{
  "docId": "019de073-5c75-763a-a0f1-d995dc5da488",
  "docSlug": "01bee26c2c6ee992ec5e01a8e02dc689",
  "documentTitle": "Myovant Sciences | Results Presentation Deck | 34 slides",
  "authorId": "myovant-sciences",
  "authorName": "Myovant Sciences",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 34,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "disclaimer",
  "function": "other",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-5c75-763a-a0f1-d995dc5da488/3",
  "deckHref": "/decks/019de073-5c75-763a-a0f1-d995dc5da488",
  "deckJsonHref": "/decks/019de073-5c75-763a-a0f1-d995dc5da488.json",
  "deckAnchorHref": "/decks/019de073-5c75-763a-a0f1-d995dc5da488#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "disclaimer",
      "text": "This presentation contains forward-looking statements, including without limitation, statements related to: Myovant’s aspiration to redefine care for women and for men; the expectations that MYFEMBREE’s approval in the U.S. for use by patients with endometriosis would contribute to significant growth opportunities; the timeline and expectations regarding the launch of MYFEMBREE for the management of moderate to severe pain associated with endometriosis by Myovant and Pfizer in the U.S.; the anticipated timeline of commercial coverage for MYFEMBREE endometriosis patients; the expectations of extending support for endometriosis patients; as well as statements related to Myovant’s financial position, commercial execution success, market leadership, patient impact, and targeted pipeline investments and focus of new pipeline programs; Myovant’s position for its corporate and business development opportunities; the timing and expectations of potential regulatory submissions, including the timing and expectation of submitting the MYFEMBREE sNDA to FDA based on 2-year data in endometriosis; commercial launches by Myovant and/or its partners; anticipated regulatory review results; and Myovant’s business strategies, financial condition and trends, competitive position, potential growth opportunities, and expectations or probabilities for success. Forward-looking statements can be identified by the use of words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “to be,” “will,” “would,” or the negative or plural of these words or other similar expressions or variations, although not all forward-looking statements contain these identifying words. Myovant cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors known and unknown that could cause actual results and the timing of certain events to differ materially from future result expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those risks discussed under the heading “Risk Factors” in Myovant’s Quarterly Report on Form 10-Q filed on July 27, 2022, as such risk factors may be amended, supplemented or superseded from time to time. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for its management to predict all risk factors, nor can Myovant assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, Myovant undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4eab588c-f3b6-4df7-aff8-9fd593a6e219",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Forward-Looking Statements",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f9f6da5-8343-423f-90a8-b6600ce11417",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}